Inovio sets October 2026 approval target for INO-3107. The biotech company announced a Prescription Drug User Fee Act decision date of October 30, 2026, for its INO-3107 candidate during Q4 2025 earnings. The company is pursuing accelerated approval pathways and has extended its cash runway into the fourth quarter of 2026, providing financial stability through the critical regulatory review period. INO-3107 represents a key pipeline asset for the company's near-term growth prospects. The extended cash position allows Inovio to execute its commercial launch strategy while awaiting regulatory feedback. Investors will closely monitor the FDA review process and any updates on accelerated approval discussions, which could significantly impact the company's timeline and market positioning in its therapeutic focus areas.
Post from MarketNews_en
Log in to interact with content.